IRadimed Corp. (IRMD)

Over the past six months, IRadimed Corp. stock has increased significantly, reaching a new 52-week high in October 2025. The company reported record revenue and EPS in both Q1 and Q2 2025 and raised its full-year guidance. A quarterly dividend of $0.17 per share was announced. Analyst ratings were upgraded, but there has been insider selling by the CEO and a director.

Demand for IRadimed Corp.'s products is supported by an aging population and increasing MRI volumes. The company anticipates continued demand for portable MRI devices and an IV infusion pump replacement cycle to drive growth. Historically, October has shown a "long bias" for the stock, according to seasonality analysis.

IRadimed Corp. specializes in MRI-compatible patient care products, operating in the Healthcare sector, including Medical/Dental Instruments, Medical Devices, Drug Delivery Devices, and Monitoring Equipment. The company focuses on creating non-magnetic devices for safe operation within MRI environments. Key products include the MRidium MRI Compatible IV Infusion Pump System, which is the only non-magnetic system cleared in the market as of Q2 2025, the MRI Compatible Patient Vital Signs Monitoring System (INVIVO series, Iradimed 3880), the 3600 FMD1 Ferromagnetic Detection Device, and related accessories and disposables.

IRadimed Corp. sells its products primarily to hospitals, acute care facilities, and outpatient imaging centers in the United States and internationally. The majority of the company's revenue is generated from the United States, with domestic sales comprising 89% of total revenue in Q2 2025, up from 86% a year prior.

IRadimed Corp. has maintained a positive brand reputation over the past year. The company was recognized on Forbes' lists of "America's Most Successful Small-Cap Companies" and "America's Best Small Companies." The FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System in Q1 2025 is a significant positive event. The withdrawal of a competitor's product has solidified IRadimed's market position as the only non-magnetic IV infusion pump system cleared in the market as of Q2 2025.

IRadimed Corp. has a significant portion of its shares held by institutional investors and individual insiders. Key institutional shareholders include BlackRock, Inc., Nine Ten Capital Management LLC, and Vanguard Group Inc. The CEO, Roger E. Susi, is the largest individual shareholder. Individual insiders collectively own 36.6% of the company, while institutions hold 48.7%, and the general public holds 7.83%.